1) | For complete prescribing information, see device instructions for use. |
2) | Kaufman J, Green JB, Cazzaniga A, Canty DJ, Tims E, Waugh J. A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects With Axillary Hyperhidrosis. Dermatol Surg. 2022;48(11):1220-1225. doi:10.1097/DSS.0000000000003598. |
3) | https://candesant.com/patents/ |
4) | Glaser DA, Green L, Kaminer M, Smith S, Pariser D. Outcomes from the SAHARA Clinical Study on the TAT Patch for Excessive Axillary Sweating or Primary Axillary Hyperhidrosis (abstract). Late-breaking oral presentation at: American Academy of Dermatology annual meeting; March 17-21 (presented March 18, 10:10 am CT), 2023; New Orleans, Louisiana. |
5) | Jacob C, Green L. Quality of Life Improvement shown during SAHARA Clinical Study on the TAT Patch for Excessive Axillary Sweating or Primary Axillary Hyperhidrosis. Presentation abstract for Cosmetic Boot Camp (CBC) conference, June 22-25, 2023, Aspen, Colorado. |
To learn more about the science behind the Brella® SweatControl Patch and Candesant’s patented targeted alkali thermolysis (TAT) technology, based on the scientific principle that thermal energy is generated when sodium comes in contact with water,2,3 please click play on the video below.
Brella is proven to achieve key efficacy endpoints, including significant reductions in HDSS* and GSP,** with significant improvements in Quality of Life4
The majority of Brella-treated patients experienced
50%or greater reduction in sweat
production based on GSP4
HDSS* and GSP** Efficacy Endpoints
(at 4 weeks post-treatment)
Percent of Participants or
Gravimetric Sweat Production (GSP)
Primary Endpoint: Percent of participants achieving HDSS 1 or 2
Percent of participants achieving 2 points or greater improvement in HDSS
Percent of participants achieving 50% or greater reduction in gravimetric sweat production (GSP)
Mean reductions in GSP (mg produced in 5 min.)
Level of Bother and Impact of Sweat
(at 4 weeks post-treatment)
Reductions in level of Bother and
Impact on Daily Activities (5-point scale)
Reductions in sweat level of
Bother (5-point scale)
Reductions in sweat level of Impact on Daily Activities (5-point scale)
*HDSS- Hyperhidrosis Disease Severity Scale
**GSP- Gravimetrio Sweat Production
of patients, after one Brella treatment, indicated that sweat never or sometimes interfered with daily activities4
64%
of patients, after one Brella treatment, indicated that sweat never or sometimes interfered with daily activities4
LASTING
RESULTS
48% and 43% of Brella-treated patients maintained reduced underarm sweating at weeks 14 and 16, respectively4
QUALITY
OF LIFE
Brella is proven to significantly reduce excessive underarm sweat production and its negative impact on quality of life, including taking multiple showers per day, frequently changing shirts, and avoiding social situations. Brella also significantly reduces frustration and embarrassment and improves confidence.5
Brella is proven to significantly reduce excessive underarm sweat production and its negative impact on quality of life, including taking multiple showers per day, frequently changing shirts, and avoiding social situations. Brella also significantly reduces frustration and embarrassment and improves confidence.5
Brella was well tolerated. All adverse events were mild or moderate and transient. 78% of Brella-treated subjects reported no adverse events. 22% of Brella-treated subjects reported mild to moderate adverse events, such as mild irritation and redness, that mostly resolved within 2 weeks.4
Brella-treated patients experienced a significant physical and emotional improvement in quality of life5
SAHARA 7 Sweat Stressors: Negative Impact of Sweat on Daily Quality of Life (QoL) & Positive Impact of Brella™ at 4 and 12 Weeks
Before Brella Treatment
(Baseline)
4 weeks after Brella
(Brella patients improved)
12 weeks after Brella
(Brella patients improved)
Seven Questions from the SAHARA Clinical Study designed to assess the impact of sweating on both physical activities and psycho-social factors
The Brella SweatControl Patch offers your patients a single-use, disposable, in-office treatment that’s quick, comfortable, non-invasive, needle-free with no downtime, and can easily fit into current aesthetic treatment regimens.
Patients report seeing results within a few days after receiving a single treatment.
Clean both axillae and examine to confirm they are free from any skin conditions.
Apply the Patch to a clean and dried underarm, smoothing to ensure full contact.
Gently massage the back of the Patch during treatment with gloved fingers. Treatment time depends on how much and how much and how quickly the patient sweats, so more sweat may require less treatment time. The goal is to treat to tolerability, so it is critical to continuously ask your patient how they are feeling. If your patient reports feeling a burn or burning sensation, an “ouch”, or a pain level of 7 or higher out of 10, immediately remove the patch and begin the deactivation process. After Deactivating the Patch (per steps below), clean the patient’s underarm. Repeat the process with a new Patch for the second underarm.
Follow the Deactivation Kit steps to properly deactivate and dispose of the used Patches.
See Instructions for Use for complete treatment process.